量子点应用于人骨肉瘤HOS细胞系研究的生物毒性评价

目的:将合成的两种量子点应用于研究人骨肉瘤HOS细胞系,初步检测其生物毒性,以确定本研究所制备量子点可否应用于骨肉瘤的基础研究。方法:将生长良好的HOS细胞与制备的两种量子点分别共培养,使用MTT试剂盒检测不同时间点细胞活性,实验进行三次,取其平均值,分析所得数据,并绘制出量子点浓度-细胞活性曲线,分析得出两者之间的量效关系。结果:1.4μM的CdTe/ZnS QDs和0.275μM的Cd Te/Cd S QDs分别是本实验中对HOS细胞的最高毒性浓度。较短时间(30 min)的暴露分别导致了48.6±0.9%和31.9±0.8%的细胞死亡,3 h后分别有33.7±2.3%和49.4±1.1%的细胞存活。而在孵育了18 h之后,只有28.0±1.6%和15.3±1.6%的细胞存活。我们可以观察到均为典型的时间/浓度曲线。结论:选用适宜浓度以及共培养时间,本实验制备的量子点完全可以满足纳米量子点粒子使用于HOS细胞研究的基本生物学条件,可以进行人骨肉瘤HOS细胞测温等的一些列实验操作。由于量子点自身优越的光学性能以及可接受的生物安全性,在肿瘤研究领域具有很大的潜力,将会成为肿瘤示踪、检测、以及靶向治疗新的有力工具。

The Biological Toxicity Study of QuantumDots Applied in the Human Osteosarcoma HOS Cell Line

Objective:Two kinds of quantum dots (QDs) was applied to study human osteosarcoma HOS cell line, preliminary testing its biological toxicity, in order to determine the preparation that the quantum dots we manufacture can be applied in the basic research of osteosarcoma.Methods:Co-culture the well grow HOS cells with the two kind of QDs respectively, by using the MTT kit to test thrice the cell viability of different point in time, calculated the average and analyzed the data, then draw the curve of QDs concentration-cell viability, got the dose-effect relationship.Results:1.4 uM CdTe/ZnS QDs and 0.275 uM CdTe/CdS QDs were the highest concentration react with HOS cells, respectively. For short time (30 mins) exposure led to 48.6± 0.9 % and 31.9± 0.8 % cells death, respectively. And after 3 hrs, there were still 33.7± 2.3 %and 49.4± 1.1 %cells alive. And after reacting for 18 hrs, 28.0± 1.6 % and 15.3 ± 1.6 % cell survival. The curve of QDs concentration-cell viability was a typical time/concentration-dependent curve.Conclusion:By chooseing appropriate concentration and co-culture time, the QDs we made can satisfy the basic biological condition that applied in HOS cell line, and proper use to the osteosarcoma basic research.Because of the predominant optical performance and acceptable biosecurity, QDs have a great potential in the tumor research field, and will be powerful instrument for tumor labeling, detection, and targeted therapy.